Thrombosis in pregnancy: maternal and fetal issues (Q33601741)

28 July 2017

1 reference

title

Thrombosis in pregnancy: maternal and fetal issues (English)

1 reference

28 July 2017

0 references

I A Greer

1

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 April 1999

1 reference

28 July 2017

1 reference

28 July 2017

volume

353

1 reference

28 July 2017

issue

9160

1 reference

28 July 2017

page(s)

1258-1265

1 reference

Thrombosis prophylaxis in obstetrics and gynaecology.

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Increased thrombin generation in women with recurrent miscarriage

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Venous thromboembolic disease in obstetrics and gynaecology: the Scottish experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Venous thrombosis: a multicausal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Variability of the response to activated protein C during normal pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

A mutation in the prothrombin gene contributing to venous thrombosis during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Hyperhomocysteinemia as a risk factor for deep-vein thrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Second-trimester pregnancy loss is associated with activated C resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Activated protein C resistance can be associated with recurrent fetal loss

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

The factor V Leiden mutation is not a common cause of recurrent miscarriage

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

First-trimester repeated abortion is not associated with activated protein C resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Placental thrombosis and second trimester miscarriage in association with activated protein C resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Increased fetal loss in women with heritable thrombophilia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Activated protein C resistance and adverse pregnancy outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

The factor V Leiden mutation may predispose women to severe preeclampsia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Effects of folic acid and vitamin B6 supplementation on women with hyperhomocysteinemia and a history of preeclampsia or fetal growth restriction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Preeclampsia is associated with a reduced response to activated protein C

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Increased frequency of genetic thrombophilia in women with complications of pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Thrombocytopenia, antithrombin deficiency and extensive thromboembolism in pregnancy: treatment with low-molecular-weight heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Technical note: compression stockings and posture: a comparative study of their effects on the proximal deep veins of the leg at rest

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Low-molecular-weight heparin for immediate management of thromboembolic disease in pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Anti-activated factor X profiles in pregnant women receiving antenatal thromboprophylaxis with enoxaparin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Resistance to activated protein C due to a factor V gene mutation The most common inherited risk factor of thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2910265-9

7 January 2021

10.1016/S0140-6736(98)10265-9

Identifiers

DOI

1 reference

28 July 2017

1 reference